52727-95-4

Basic information

• Product Name: 4-Bromomethylphenyl acetate
• Synonyms: 4-Bromomethylphenyl acetate;Phenol, 4-(broMoMethyl)-, acetate;p-Acetoxybenzyl Bromide;4-(Bromomethyl)phenylacetate,tech;4-acetoxybenzyl bromide
• CAS NO: 52727-95-4
• Molecular Formula: C₉H₉BrO₂
• Molecular Weight: 229.07056
• Mol File: 52727-95-4.mol
• Article Data: 19

Chemical Properties

• Melting Point: 54-55 °C
• Boiling Point: 118-122 °C(Press: 1.5 Torr)
• Appearance: /
• Density: 1.463±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• CAS DataBase Reference: 4-Bromomethylphenyl acetate(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Bromomethylphenyl acetate(52727-95-4)
• EPA Substance Registry System: 4-Bromomethylphenyl acetate(52727-95-4)

Safety Data

• Hazardous Substances Data: 52727-95-4(Hazardous Substances Data)

Usage

General Description

4-Bromomethylphenyl acetate is a chemical compound that consists of a benzene ring with a bromine atom and a methyl group attached, as well as an acetate group. It is used in organic synthesis as a building block for the preparation of various pharmaceuticals and agrochemicals. 4-Bromomethylphenyl acetate is also used in the manufacturing of perfumes and flavorings due to its aromatic properties. It is important to handle 4-Bromomethylphenyl acetate with care, as it is a hazardous substance and can cause irritation to the skin, eyes, and respiratory system upon exposure.

Upstream product

• 77-48-5 1,3-dibromo-5,5-dimethylimidazolidine-2,4-dione 
• 140-39-6 1-acetoxy-4-methylbenzene 
• 6309-46-2 4-acetoxybenzyl alcohol 
• 623-05-2 (4-hydroxyphenyl)methanol 
• 228106-33-0 4-trityloxymethyl-phenol 
• 228106-32-9 acetic acid 4-trityloxymethyl-phenyl ester 
• 106-44-5 p-cresol 
• 123-08-0 4-hydroxy-benzaldehyde 

Downstream Products

• 2727-34-6 3-(4-acetoxy-benzyl)-3H-benzothiazole-2-thione 
• 2727-33-5 1-acetoxy-4-benzothiazol-2-ylsulfanylmethyl-benzene 
• 228106-20-5 Acetic acid 4-((2R,3S,4S,5R,6S)-3,4,5-tris-benzyloxy-6-methoxy-tetrahydro-pyran-2-ylmethoxymethyl)-phenyl ester 
• 27079-92-1 4-(bromomethyl)phenol 
• 501-97-3 4-hydroxyphenylpropionic acid 
• 5597-50-2 3-(4-hydroxyphenyl)propionic acid methyl ester 

Relevant articles and documents

The synthesis and antistaphylococcal activity of 9, 13-disubstituted berberine derivatives

A series of novel 9, 13-disubstituted berberine derivatives have been synthesized and evaluated for the antibacterial activities against Staphylococcus aureus, including Newman strain and multidrug-resistant strains (NRS-1, NRS-70, NRS-100, NRS-108, and NRS-271). Compound 20 shows the most potent activity against the growth of Newman strain, with a MIC value of 0.78?μg/mL, which is comparable with the positive control vancomycin. In addition, compound 20, 21, and 33 are highly antistaphylococcal active against five strains of multidrug-resistant S.?aureus, with MIC values of 0.78–1.56?μg/mL. Of note, theses antibacterial active compounds have no obvious toxicity to the viability of human fibroblast (HAF) cells at the MIC concentration.

Design, synthesis, and biological evaluation of dual targeting inhibitors of histone deacetylase 6/8 and bromodomain BRPF1

Histone modifying proteins, specifically histone deacetylases (HDACs) and bromodomains, have emerged as novel promising targets for anticancer therapy. In the current work, based on available crystal structures and docking studies, we designed dual inhibitors of both HDAC6/8 and the bromodomain and PHD finger containing protein 1 (BRPF1). Biochemical and biophysical tests showed that compounds 23a,b and 37 are nanomolar inhibitors of both target proteins. Detailed structure-activity relationships were deduced for the synthesized inhibitors which were supported by extensive docking and molecular dynamics studies. Cellular testing in acute myeloid leukemia (AML) cells showed only a weak effect, most probably because of the poor permeability of the inhibitors. We also aimed to analyse the target engagement and the cellular activity of the novel inhibitors by determining the protein acetylation levels in cells by western blotting (tubulin vs histone acetylation), and by assessing their effects on various cancer cell lines.

Synthetic process of esmolol intermediate 3-(4-hydroxyphenyl) methyl propionate

The invention belongs to the field of medicinal chemical industry, and particularly relates to a synthetic process of an esmolol intermediate 3-(4-hydroxyphenyl) methyl propionate. The synthetic process comprises the steps of: adopting p-methyl phenol and acetic anhydride as raw materials, performing an acylation reaction to obtain (4-methyl) phenol acetate, performing a halogenation reaction between the obtained (4-methyl) phenol acetate and a halogenating reagent, then carrying out a substitution reaction between the halogenated product and diethyl malonate, performing hydrolysis decarboxylation, and then carrying out an esterification reaction between the obtained product with methanol to obtain the 3-(4-hydroxyphenyl) methyl propionate. Through the route of the synthetic process, the process conditions are optimized, and the synthetic process has simple operation, easy and available raw materials and low cost; and the 3-(4-hydroxyphenyl) methyl propionate is obtained finally through acylation, halogenation, substitution, hydrolysis decarboxylation and the esterification reaction, and the synthetic process has a good industrial value and a total yield of 48.8%.